GNOMX Corp. develops host-response epigenetic and AI diagnostic tests for infectious disease. Its stated products in development include ReAdmitPredict for predicting sepsis patient hospital readmission risk and LymeScreen Dx for early detection of acute Lyme disease; the company is also developing PCR-based laboratory-developed testing.
BARDA DRIVe Phase 1 contract
Compliance program
Scanogen IncBaltimore-based Scanogen develops molecular diagnostic systems that detect infectious-disease biomolecules directly from body fluids, using its proprietary Single Molecule And Rapid Tethering (SMART) technology. The company is focused on a sample-to-answer platform for point-of-care testing, including an assay designed to identify bloodstream-infection pathogens from whole blood within two hours. Scanogen has received more than $20 million in NIH grants and collaborates with Johns Hopkins University and federal agencies in the Washington, D.C., area.BALTIMORE, MD
Tetracore, IncFor more than 20 years, Rockville-based Tetracore, Inc. has developed diagnostic reagents, assays, and instruments that detect infectious diseases and biothreat agents. Its work spans human and animal health, domestic preparedness, and forensic biology, including the T-COR 8 portable PCR thermocycler and the BioThreat Alert testing platform. Tetracore’s quality system is certified to ISO 13485 and ISO 9001, with laboratories accredited to ISO/IEC 17025.ROCKVILLE, MD
Prompt DiagnosticsBaltimore-based Prompt Diagnostics develops portable molecular diagnostic platforms that bring laboratory-quality PCR testing to the point of care, with results in under 20 minutes. Co-founded by biomedical engineer Alex Trick and Johns Hopkins professor Tza-Huei (Jeff) Wang, the company built its platform around magnetofluidic cartridge technology invented during Trick’s doctoral research. Prompt is applying that technology to infectious-disease testing, including work on HIV, syphilis, and drug-resistant gonorrhea in low-resource settings.BALTIMORE, MD